Key facts
- It has raised $10.6M; the latest was Early Stage VC ($8.3M) in Mar 2025.
- Notable investors include Tech Incubator Program for Startup, Partners Investment, Meritz Securities, Cornerstone Investment Partners, Industrial Bank of Korea — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for DigmBio
- ·The full record, as it builds
Funding rounds
No funding rounds for DigmBio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About DigmBio
Developer of a novel dementia treatment designed to target the T1R3 GPCR. The company is engaged in drug development based on the novel target GPCR TASR platform by establishing an optimization program with the goal of developing undruggable target new drugs, enabling professionals to treat patients and make them fit.
- Sector
- Healthcare
- HQ
- Seongnam, South Korea
- Founded
- 2020
- Employees
- 8
- Website
- digmbio.com/
- Ownership
- Privately Held (backing)
DigmBio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in DigmBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on DigmBio in its N-PORT filings yet. We sweep new filings monthly.